T-3262に関する基礎的.臨床的研究

• 賀来 満夫他

  長崎大学医学部第二内科学教室

書誌事項

タイトル別名

• LABORATORY AND CLINICAL STUDIES ON T-3262

抄録

We carried out laboratory and clinical studies on T-3262, a new antimicrobial agent, and obtained the following results.<BR>1) Antimicrobial activity: the in vitro antimicrobial activity of T-3262 was determined against 30 standard strains and 543 clinical isolates of 16 different species by a microbroth dilution method using the Dynateck system MIC 2000 and compared with those of pipemidic acid (PPA), norfloxacin (NFLX), ofloxacin (OFLX), enoxacin (ENX) and ciprofloxacin (CPFX).<BR>Results: T-3262 showed excellent activity against both Gram-positive cocci and Gram-negative bacilli of standard strains and clinical isolates.<BR>2) Clinical efficacy and adverse reactions: 17 patients with respiratory infection (pneumonia 6, chronic bronchitis 7, diffuse panbronchiolitis 3, acute bronchitis 1) and 3 patients with dysentery were treated with T-3262.<BR>The overall efficacy rate was 84. 2%(excellent 3, good 13, fair 3, not evaluable 1).<BR>No side effect or abnormal laboratory finding was observed.<BR>We therefore conclude that T-3262 is a useful antibiotic in treating patients with respiratory and intestinal infections.

収録刊行物

• ＣＨＥＭＯＴＨＥＲＡＰＹ

  ＣＨＥＭＯＴＨＥＲＡＰＹ 36 (Supplement9-Clinical), 661-674, 1988

  公益社団法人 日本化学療法学会

キーワード

• T-3262
• ピリドンカルボン酸系抗菌剤
• 抗菌力
• 呼吸器感染症
• 腸管感染症

詳細情報

• CRID: 1390282681262420736
• NII論文ID: 130004196652
• DOI: 10.11250/chemotherapy1953.36.supplement9-clinical_661
• ISSN: 18845894
• ISSN: 00093165
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可